BioNano Genomics Inc vs ThredUp Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while ThredUp Inc trades at $6.62 (market cap $817.47M). The key difference: ThredUp Inc is far larger — about 61.9× BioNano Genomics Inc's market cap, and ThredUp Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | TDUP | |
|---|---|---|
Market Cap | $13.20M | $817.47M |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $12.08 |
52-Week Low | $1.09 | $3.11 |
Enterprise Value | $15.81M | $820.21M |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
TDUP trades at $6.18, down 6.36% over 24 hours, with a mixed technical picture showing bullish moving averages but bearish oscillators. The company reported Q1 2026 revenue of $81.7 million, a 15% year-over-year increase, though net losses persist. Recent news highlights the launch of a peer-to-peer marketplace and AI-driven shopping features, signaling innovation efforts. Analyst sentiment remains positive with a consensus price target of $6.90 and 57% buy ratings.
The outlook hinges on TDUP's ability to leverage AI for cost reduction and growth in its resale platform, but risks include sustained profitability challenges and competitive pressures. With cash flow improving and debt levels manageable, the stock offers speculative upside if execution aligns with bullish analyst expectations.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →